177 related articles for article (PubMed ID: 18716369)
1. Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Imanishi T; Ikejima H; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertens Res; 2008 Jun; 31(6):1199-208. PubMed ID: 18716369
[TBL] [Abstract][Full Text] [Related]
2. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits.
Imanishi T; Kuroi A; Ikejima H; Kobayashi K; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertens Res; 2008 Mar; 31(3):575-84. PubMed ID: 18497479
[TBL] [Abstract][Full Text] [Related]
3. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
4. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Kumai T; Oonuma S; Matsumoto N; Takeba Y; Taniguchi R; Kamio K; Miyazu O; Koitabashi Y; Sekine S; Tadokoro M; Kobayashi S
Life Sci; 2004 Mar; 74(17):2129-42. PubMed ID: 14969717
[TBL] [Abstract][Full Text] [Related]
5. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
[TBL] [Abstract][Full Text] [Related]
6. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
Imanishi T; Ikejima H; Tsujioka H; Kuroi A; Kobayashi K; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertension; 2008 Mar; 51(3):734-41. PubMed ID: 18227404
[TBL] [Abstract][Full Text] [Related]
7. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
9. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Kato M; Sada T; Mizuno M; Kitayama K; Inaba T; Koike H
J Cardiovasc Pharmacol; 2005 Oct; 46(4):556-62. PubMed ID: 16160612
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
Bayorh MA; Ganafa AA; Eatman D; Walton M; Feuerstein GZ
Am J Hypertens; 2005 Nov; 18(11):1496-502. PubMed ID: 16280288
[TBL] [Abstract][Full Text] [Related]
11. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
[TBL] [Abstract][Full Text] [Related]
12. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Thai H; Guarraia D; Johnson N; Goldman S; Gaballa MA
J Cardiovasc Pharmacol; 2007 Dec; 50(6):703-7. PubMed ID: 18091589
[TBL] [Abstract][Full Text] [Related]
13. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor.
Imanishi T; Kobayashi K; Kuroi A; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertension; 2006 Dec; 48(6):1058-65. PubMed ID: 17060506
[TBL] [Abstract][Full Text] [Related]
15. L-arginine plus atorvastatin for prevention of atheroma formation in genetically hypercholesterolaemic rabbits.
Rasmusen C; Moinard C; Martin C; Tricottet V; Cynober L; Couderc R
Br J Nutr; 2007 Jun; 97(6):1083-9. PubMed ID: 17391569
[TBL] [Abstract][Full Text] [Related]
16. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
David S; Kümpers P; Lukasz A; Kielstein JT; Haller H; Fliser D
J Hypertens; 2009 Aug; 27(8):1641-7. PubMed ID: 19390459
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase.
Savoia C; Ebrahimian T; He Y; Gratton JP; Schiffrin EL; Touyz RM
J Hypertens; 2006 Dec; 24(12):2417-22. PubMed ID: 17082724
[TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone on nitric oxide bioavailability measured using a catheter-type nitric oxide sensor in angiotensin II-infusion rabbit.
Imanishi T; Kuroi A; Ikejima H; Kobayashi K; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertens Res; 2008 Jan; 31(1):117-25. PubMed ID: 18360026
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits.
Oubiña MP; de las Heras N; Cediel E; Sanz-Rosa D; Aragoncillo P; Díaz C; Hernández G; Lahera V; Cachofeiro V
Clin Sci (Lond); 2003 Dec; 105(6):655-62. PubMed ID: 12848617
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein.
Ma FX; Liu LY; Xiong XM
Acta Pharmacol Sin; 2003 Oct; 24(10):1027-32. PubMed ID: 14531947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
